Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Aug 31;14(8):2912-2917.
doi: 10.21037/tlcr-2025-363. Epub 2025 Aug 11.

The OPEN trial-from the darkness, comes light

Richard Pham  1 , Surein Arulananda  1   2   3
Affiliations
Editorial

The OPEN trial-from the darkness, comes light

Richard Pham et al. Transl Lung Cancer Res. .
No abstract available

Keywords: Epidermal growth factor receptor-mutant (EGFR-mutant); non-small cell lung cancer (NSCLC); osimertinib; poor performance status (poor PS).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-2025-363/coif). S.A. receives speaker fees from Merck-Sharpe & Dohme, Astra Zeneca, Roche, Bristol-Myer Squibb, Merck Serono, Takeda, Medwise consulting and Amgen; receives travel support from Astra Zeneca, Roche, Merck-Sharpe & Dohme and Pfizer; and is on the advisory board for Roche, BeiGene, Amgen, Bayer, Astra Zeneca, Merck-Sharpe & Dohme, Johnson & Johnson, Bristol-Myer Squibb and Medison. The other author has no conflicts of interest to declare.

Comment on

References

    1. de Koning HJ, van der Aalst CM, de Jong PA, et al. Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. N Engl J Med 2020;382:503-13. 10.1056/NEJMoa1911793 - DOI - PubMed
    1. Lung Cancer Incidence and Mortality with Extended Follow-up in the National Lung Screening Trial . J Thorac Oncol 2019;14:1732-42. 10.1016/j.jtho.2019.05.044 - DOI - PMC - PubMed
    1. Hill W, Lim EL, Weeden CE, et al. Lung adenocarcinoma promotion by air pollutants. Nature 2023;616:159-67. 10.1038/s41586-023-05874-3 - DOI - PMC - PubMed
    1. Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med 2018;378:113-25. 10.1056/NEJMoa1713137 - DOI - PubMed
    1. Nakashima K, Kimura M, Akamatsu H, et al. Osimertinib for patients with EGFR T790M mutation-positive non-small-cell lung cancer and a poor performance status. Jpn J Clin Oncol 2019;49:671-5. 10.1093/jjco/hyz041 - DOI - PubMed

LinkOut - more resources